| Industry | 制造业 | ||||||||||||||||||||||||
| Company Introduction | 海森药业成立于1998年，是一家专业从事化学药品原料药及中间体研发、生产和销售的高新技术企业。连续多年获得东阳市“工业强市贡献奖”、东阳市 “纳税百强”等荣誉称号。经过多年的发展，公司已经形成了以消化系统类、解热镇痛类和心血管类原料药为主，以抗抑郁类、抗菌类等原料药为辅，同时以抗 病毒类、非甾体抗炎类等在研原料药与制剂为预备的产品体系。公司的产品覆盖面广，能够满足国内外客户的多元化需求，为公司的可持续发展奠定了良好的 基础。公司始终把加强技术创新放在首位，坚持创新的发展理念，用技术创新促进公司不断转型升级。长期以来坚持以市场为导向，产学研相结合，形成技术 攻关平台，持续提升公司的技术水平和研发实力。经过多年的平台搭建、人才储备、研发投入和技术积累，公司已经拥有一支在原料药研发方面具有丰富经 验、结构合理的人才队伍，研发队伍中既有享受国务院特殊津贴专家，也有国内个别产品领域的早期开拓者。公司不仅注重新技术产业化，同时注重市场全球 化。经过多年的管理积累与市场开拓，公司已成为硫糖铝、阿托伐他汀钙等产品国内主要生产厂家之一，且在全球市场上也取得了较高的市场占有率。公司在 质量控制方面具有成熟的技术与丰富的经验，在市场上享有一定的知名度和认可度。海森药业遵循“诚信共赢、安全规范、团队协作、客户至上、持续创新”的 核心价值观，建立了高标准的质量管理体系、环境管理体系、职业健康安全管理体系，为企业健康发展保驾护航。以“拥有多个领先的医药产品，具备持续创 新的组织能力，成为公众尊敬、客户信任、员工幸福的一流企业”的发展愿景，努力践行“致力于不断研发、生产与推广卓越的医药产品与服务，为持续提升人 们生命质量而努力”的使命。结合公司自身经营的经验与优势，公司已经着手推进向化学药品制剂研发、生产与销售的产业链延伸，以实现向“中间体、原料药 和制剂”一体化产业链的升级。 | ||||||||||||||||||||||||
| Main Business | 从事化学药品原料药及中间体研发、生产和销售。 | ||||||||||||||||||||||||
| Legal Representative | 王式跃 | ||||||||||||||||||||||||
| Top Executives |
|
||||||||||||||||||||||||
| Top 5 Shareholder |
|
||||||||||||||||||||||||
| Company Secretary | 胡康康 | ||||||||||||||||||||||||
| Solicitors | 北京德恒律师事务所 | ||||||||||||||||||||||||
| Auditors | 立信会计师事务所（特殊普通合伙） | ||||||||||||||||||||||||
| Tel No | 0579-86768756 | ||||||||||||||||||||||||
| Fax No | 0579-86768187 | ||||||||||||||||||||||||
| Website | www.haisenpharma.com | ||||||||||||||||||||||||
| hsxp@zjhaisen.com | |||||||||||||||||||||||||
| Company Address |
|
||||||||||||||||||||||||
| Listing Date | 10/04/2023 | ||||||||||||||||||||||||
| Shares Capital |
|
||||||||||||||||||||||||
| EPS(RMB)* | ¥ 1.680 | ||||||||||||||||||||||||
| DPS(RMB)* | ¥ 0.500 | ||||||||||||||||||||||||
| NBV Per Share(RMB)* | ¥ 18.373 | ||||||||||||||||||||||||
| Market Capitalization(RMB) | 0.816B |
 |
Only Chinese content is avaliable |
|
N
/
N
: Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SH-HK Ex-Northbound trade (sell only)
|
|
|
N
/
N
: Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
|
|
| * | Unadjusted Data |
| Information provided by: etnet | ||
| Terms and Conditions | ||
| Risk Disclosure: |
| The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone. |
| Disclaimer: |
| This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Chiyu Banking Corporation Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information. |